2025 Asia-Pacific Allergy Immunotherapy Revenue Opportunities Report
Description
The 2025 Asia-Pacific Allergy Immunotherapy Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asia-Pacific allergy immunotherapy market are ALK-Abelló A/S, Merck KGaA (Allergopharma), Stallergenes Greer International AG, and Viatris, Inc. (Mylan N.V.). ALK-Abelló leads with a strong presence and robust product portfolio, expanding in Asia-Pacific especially through subcutaneous and sublingual immunotherapy products. Merck KGaA, through its subsidiary Allergopharma, is a major player specializing in allergen extracts and immunotherapy for various allergies including allergic rhinitis and asthma. Stallergenes Greer dominates the food allergy immunotherapy niche, particularly through PALFORZIA for peanut allergies, driving the market in the region. Viatris (formerly Mylan) is also significant, focusing on expanding allergy treatment access in Asia-Pacific.
These companies benefit from rapid growth in the Asia-Pacific market due to increasing allergy prevalence, government support (especially in China and Japan), urbanization, and rising public awareness. The Asia-Pacific market is projected to grow at a CAGR above 10%, with China, Japan, India, and South Korea as key contributors. They offer both subcutaneous and sublingual immunotherapy options, catering to allergic rhinitis, asthma, and food allergies, with a growing emphasis on personalized immunotherapy and novel formulations to meet regional needs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asia-Pacific allergy immunotherapy market are ALK-Abelló A/S, Merck KGaA (Allergopharma), Stallergenes Greer International AG, and Viatris, Inc. (Mylan N.V.). ALK-Abelló leads with a strong presence and robust product portfolio, expanding in Asia-Pacific especially through subcutaneous and sublingual immunotherapy products. Merck KGaA, through its subsidiary Allergopharma, is a major player specializing in allergen extracts and immunotherapy for various allergies including allergic rhinitis and asthma. Stallergenes Greer dominates the food allergy immunotherapy niche, particularly through PALFORZIA for peanut allergies, driving the market in the region. Viatris (formerly Mylan) is also significant, focusing on expanding allergy treatment access in Asia-Pacific.
These companies benefit from rapid growth in the Asia-Pacific market due to increasing allergy prevalence, government support (especially in China and Japan), urbanization, and rising public awareness. The Asia-Pacific market is projected to grow at a CAGR above 10%, with China, Japan, India, and South Korea as key contributors. They offer both subcutaneous and sublingual immunotherapy options, catering to allergic rhinitis, asthma, and food allergies, with a growing emphasis on personalized immunotherapy and novel formulations to meet regional needs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
